Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Prasugrel Outperforms Clopidogrel In Head-To-Head Test For Recurrent Events

This article was originally published in The Pink Sheet Daily

Executive Summary

Lilly and Daiichi Sankyo await Sept. 26 FDA action date for anti-platelet drug slated to take on Bristol’s Plavix.

You may also be interested in...

Daiichi Sankyo Expands European Sales Presence By Hiring 130 Merck KGaA Reps

Goal is a 70/30 split of ROW and Japanese revenues, firm says.

Bristol Readies For Prasugrel’s Impact On Plavix, Files DPP-4 Inhibitor

Despite downplaying any concern, Bristol-Myers Squibb is preparing for a potential challenge to its blockbuster anti-clotting drug Plavix from Lilly/Daiichi Sankyo's Effient (prasugrel)

Prasugrel Delay Shifts Focus To Possible August Advisory Committee

FDA extends user fee date for the novel anti-platelet drug to Sept. 26.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts